MENS logo

JYONG BIOTECH LTD

MENSNASDAQ
🏆 #3794 by market capUS Equity
$2.07▲ $0.02 (+0.98%)
Latest quote
🔔
Track MENS
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.0%
7d▲ 21.8%
14d▲ 5.3%
30d▲ 2.5%
ytd▼ 48.3%
1y▼ 95.8%
🏦Market Cap
$157M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$2.01 – $2.07
52-Week Range
$1.43 – $61.22
Volume (shares)
6,970.008
Avg Volume (shares)
—
Shares Outstanding
76.0M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-0.08
Dividend Yield
—
Dilution (1yr)
+103626.1%
MENS logo

JYONG BIOTECH LTD

MENS
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$3M▲ +26.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$3M▼ −16.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
74.2M▲ +103626.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$17M▲ +$666K YoY
StockOtter · stockotter.space

About JYONG BIOTECH LTD

Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

GlobeNewsWire·8d ago

Jyong Biotech to Host Two-Day Investor Events in Silicon Valley and Irvine, California

New Taipei City, Taiwan/San Francisco, CA, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and c

GlobeNewsWire·14d ago

Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug Candidates

New Taipei City, Taiwan, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization o

GlobeNewsWire·Sep 3

Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow

New Taipei City, Taiwan/San Francisco, CA, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd.